挺进美女教师的蜜桃肥臀视频-同性恋一级片-同性情a三级a三级a三级-同性做爰猛烈全过程-91丨porny丨国产麻豆-91丨porny丨国产入口

美國Nanogen   
Nanogen公司成立于1993年，位于加州San Diego，是一家微電子技術(shù)與分子生物學(xué)結(jié)合的芯片專利公司。在五年和威斯康辛大學(xué)醫(yī)學(xué)院（the Medical College of Wisconsin）的合作中，Nanogen已經(jīng)研制出了自動診斷儀器，這種儀器能快速的檢測到引起敗血癥和肺炎的細(xì)菌或病毒
美國Nanogen生物技術(shù)公司（NGEN）2005年8月1日發(fā)布消息，國家傳染疾病研究所（he National Institute of Allergy and Infectious Diseases，NIH）撥款$2,500,000給Nanogen公司，用于敗血癥和“社區(qū)獲得性或群落性肺炎”類型的呼吸系統(tǒng)疾病(community-acquired pneumonia或CAP)的原位診斷研究。
2009年法國Elitech Group收購美國Nanogen
Nanogen has developed a strong product and proprietary technology base in advanced diagnostic solutions for two of the fastest growing in vitro diagnostic (IVD) markets – molecular diagnostics and rapid point-of-care testing. The role of diagnostics in healthcare is evolving rapidly buoyed by new and improved technologies that allow the advancement and decentralization of diagnostic applications. Products like those from Nanogen are quickening the pace toward personalized medicine. Both clinical laboratories and point-of-care providers are seeing strong validation of the contribution advanced diagnostic tests can have for the delivery of better, more personalized patient care. With its growing diagnostics product offering, Nanogen is poised to become a key player in this arena.

Nanogen’s products are used in multiple segments of the global IVD market - including applications in which testing is used as a prognostic indicator of disease and for ongoing monitoring of disease. Products include a broad menu of real-time PCR reagents and kits for DNA and RNA infectious disease targets as well as genotyping assays for key biomarkers in onco-hematology. The Company’s rapid tests for acute cardiac conditions and drugs of abuse are sold to customers requiring rapid results at or near the point of treatment such as emergency rooms.

All of Nanogen’s products are designed to improve the role diagnostics plays in improving individual patient care by providing more specific DNA-based results or by moving the diagnostic capability and decision closer to the patient. The strong intellectual property portfolio of advanced diagnostic technologies allows the company to bring unique solutions to the market. The IP portfolio includes: the MGB Eclipse? probes technology which is widely licensed and has proven to be a mainstay in helping to make real-time PCR a gold standard method in molecular biology research and diagnostic testing; and key patents for the reporting of multiple biomarkers in a rapid test format.